Could your Phone's camera help track thyroid eye disease?
NCT ID NCT07623993
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study explores whether a smartphone app using artificial intelligence can help people with thyroid eye disease (TED) monitor their condition from home. Participants take weekly facial photos and answer symptom questions via the app while undergoing standard non-surgical treatment. Researchers compare the app's AI-generated measurements to those taken by doctors in the clinic to see if they match. The goal is to find a simpler, more convenient way to track TED without relying solely on in-person visits.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Smartphone-based AI self-monitoring application (Glandy CAS/EXO/LID)
- What this could lead to
- If successful, this could provide a convenient, at-home way to track thyroid eye disease progression, potentially reducing the need for frequent clinic visits.
- What could go wrong
- This is an early observational study, so the AI may not match doctor assessments closely. The app is not used for real-time decisions, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults (≥19 years) with clinically diagnosed TED who are scheduled to initiate active non-surgical treatment at participating ophthalmology sites.
- Ages
-
22 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 19 years or older with a clinical diagnosis of thyroid eye disease (TED). * Patients with TED scheduled to initiate active non-surgical treatment, including but not limited to intravenous methylprednisolone, oral corticosteroids, radiotherapy, or biologic therapy. * Able to undergo baseline clinical assessment prior to initiation of the planned treatment course and expected routine follow-up evaluation during treatment, including an end-of-treatment assessment. * Able and willing to use their own smartphone to complete the study application-guided symptom questionnaire and capture standardized frontal facial images throughout the study period. * Willing to perform at least weekly home-based image capture and symptom reporting during the treatment course. * Able to participate in routine in-person follow-up visits and expected to provide at least two clinic-matched assessments, including baseline and at least one post-baseline assessment. * Voluntarily provides written informed consent to participate in the study. Exclusion Criteria: * Severe eyelid deformities, facial deformities, or other facial/periocular conditions that may interfere with standardized image acquisition or reliable AI-based image analysis. * Unable to use the study application or smartphone-based image capture procedure adequately for protocol-required self-monitoring. * Undergoing or planning to undergo surgical treatment for TED as the primary treatment modality during the study period. * History of ocular, eyelid, or orbital surgery within 3 months prior to enrollment. * Any medical, psychiatric, cognitive, or other condition that, in the investigator's judgment, may compromise protocol compliance, study participation, or data integrity. * Any other condition that the investigator judges to make the patient inappropriate for participation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Graves ophthalmopathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
3003 North First Street #221
San Jose, California, 95134, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Eye damage in Graves' disease: can early clues predict who is at risk?
- Can a pill tame thyroid eye disease?
- Could a cholesterol drug shrink eye muscle swelling in thyroid eye disease?
- Can a pill reverse eye bulging in thyroid eye disease?
- AI reads eye scans to spot thyroid disease activity and severity
- Glaucoma drug could offer simple fix for Graves' eye bulging